BMBF approves cluster for nucleic acid based therapeutics in Munich
The German Federal Ministry of Education and Research (BMBF) has selected the winners of the second round of the Clusters4Future competition. These include C-NATM, the cluster for the development of new nucleic acid based therapies in which ISAR Bioscience is involved. C-NATM is supported by the two Munich universities, the Helmholtz Center for Health Research and numerous international and biotech companies from the Munich area.
The goal of C-NATM is to invent novel therapeutics based on DNA, RNA and smaller nucleic acids. One example is the new RNA-based Corona vaccines - but these technologies go far beyond and may open a new chapter in drug therapy. The reason for this is the high specificity and “programmability” of nucleic acids.
A high-ranking committee has now selected the seven most promising applications from an initial 117. Federal Research Minister Stark-Watzinger states: “This is where promising ideas and pioneering spirit come together to courageously bring innovative research more quickly into economic and social application.”
“The success in the Future Clusters competition shows that the Munich region is the right place to develop innovative therapies,” says Professor Martin Lohse, CEO of ISAR Bioscience. “We congratulate the coordinators, Professors Thomas Carell and Stefan Engelhardt, and all those involved in this excellent effort, and we look forward to further collaborations.”
ISAR Bioscience, together with TU Munich and the start-up rnatics, is conducting research on oligonucleotide-based strategies for the treatment of inflammation and fibrosis. We are also working on ways to deliver such nucleic acid-based therapeutics to target tissues - for example, with targeted targeting methods or using lipid nanoparticles, or LNPs.
Technical University of Munich: https://www.isarbioscience.de/technische-universitaet-muenchen/